KTRA NASDAQ
Kintara Therapeutics, Inc.
1W: -96.5%
1M: -96.5%
3M: -97.6%
1Y: -99.3%
3Y: -100.0%
5Y: -99.9%
$0.22
Last traded 2024-10-17 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
$0
+0.0% ▲
Net Income
-$30M
+99.9% ▲
EPS (Diluted)
$-0.63
+47.9% ▲
EBITDA
$0
+100.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $60K | $60K | $55K | $0 | $0 |
| Gross Profit | -$60K | -$60K | -$55K | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $15M | $9M | $3M | $13.3B | $21M |
| SG&A Expenses | $8M | $5M | $6M | $4.3B | $8M |
| Operating Expenses | $23M | $15M | $8M | $17.6B | $28M |
| Operating Income | -$23M | -$15M | -$9M | $0 | $0 |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $14K | $0 | $0 | $4.1B | -$625K |
| Income Before Tax | -$23M | -$15M | -$8M | -$22.6B | -$30M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$23M | -$15M | -$9M | -$22.6B | -$30M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-25.80 | $-9.27 | $-3.23 | $-1.21 | $-0.63 |
| EBITDA | -$23M | -$15M | -$8M | $0 | $0 |
| Shares Outstanding | 974000 | 2M | 3M | 19M | 48M |